---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-363150"
form_type: "8-K"
ticker: "BCAB"
cik: "0001826892"
company_name: "BioAtla, Inc."
filed_at: "2021-12-21T23:59:59+00:00"
generated_at: "2026-06-27T23:25:52.254928+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# BioAtla appoints Edward L. Williams to Board of Directors, increases board to 8

## Summary
- Board size increased from 7 to 8; Mr. Williams appointed as Class III director effective Dec 16, 2021.
- Mr. Williams will serve on the Audit Committee.
- Received initial grant of 25,000 stock options vesting over approximately 2 years under 2020 Equity Incentive Plan.
- Former SVP Biopharmaceuticals at Novo Nordisk (2006-2017) and VP at Novartis; currently special advisor to CEO of Ascendis Pharma.
- Standard indemnification agreement entered; no related-party transactions disclosed.

## SEC filing metadata
- accession: 0001193125-21-363150
- form_type: 8-K
- ticker: BCAB
- cik: 0001826892
- company_name: BioAtla, Inc.
- filed_at: 2021-12-21T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1826892/000119312521363150/0001193125-21-363150-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1826892/000119312521363150/d275731d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-363150
- JSON: https://secwatch.observer/filing/0001193125-21-363150.json
- Plain text: https://secwatch.observer/filing/0001193125-21-363150.txt

## Key facts
- Executive change
  Edward L. Williams was appointed as Director at BioAtla, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 16, 2021, the Board of Directors (the “Board”) of BioAtla, Inc. (the “Company”) increased the size of the Board from seven directors to eight directors and appointed Edward L. (Eddie) Williams to the Board, effective December 16, 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1826892/000119312521363150/0001193125-21-363150-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.